Team VIVA!
Aussies with CVD at higher risk from COVID-19
Tracking the incidence of COVID-19 globally, it is understood that people over the age of 60 with a pre-existing chronic condition, such as cardiovascular disease (CVD) or diabetes, are considered at greater risk to serious infection and complications.1 There has been a high prevalence of CVD in those dying from COVID-19 in Italy and China, two of the worst…
Read MoreWhat’s in a name? Coining history’s deadliest pandemics
Here’s some scientific nomenclature to help kick-start your Monday! For centuries before the advent of coronavirus, many contagions, including the Bubonic Plague, syphilis, smallpox and tuberculosis, claimed the lives of hundreds of millions of people worldwide. Ironically, many of these contagions were awarded a ‘rainbow’ of names. Syphilis – a bacterial infection commonly spread by…
Read MoreAussies & Kiwis with incurable blood cancer receive newly subsidised treatment option
Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…
Read MoreNational Wear Red Day – Heart Research Australia
It’s that time of year again when you get in trouble with your significant other for forgetting a Valentine’s Day gift or have to pay triple the price for a bunch of sad looking roses from the supermarket on the way home! But for us at VIVA! Communications, February 14 is an important day as…
Read MoreOvarian Cancer Awareness Month
In Australia, around 1,500 women are diagnosed with ovarian cancer each year. Less than half (45%) survive past 5 years. This February is Ovarian Cancer Awareness Month, a month dedicated raising awareness for earlier testing and diagnosis. For more information, check out our infographic or head over to: https://bit.ly/2SqEuG0,
Read More